A candidate dengue vaccine developed by scientists at the National Institutes of Health has been found to be safe and to stimulate a strong immune response in most vaccine recipients, according to results from an early-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. The trial results appeared in the January 17 issue of the Journal of Infectious Diseases.

One Response to “Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial”

Leave a Reply

Contact Us | Privacy Statement